Drug Trial Radar · NCT06250946
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .
Last checked: Nov 20, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
235
Actual
Start
Feb 23, 2024
Primary completion
Jan 22, 2025
Study completion Jan 22, 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese Subjects.
Conditions
- Overweight and Obesity
Interventions
HRS-7535;PlaceboDrug
HRS-7535;Placebo
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baseline at Week 26Time frame: Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.